Literature DB >> 3724175

The effect of tumor size and axillary lymph node metastasis on estrogen and progesterone receptors in primary breast cancer.

A A Alghanem, S Hussain.   

Abstract

We evaluated the estrogen receptors (Er) and the progesterone receptors (Pr) in 209 female patients with primary breast cancer. There is statistically a very highly significant negative correlation between the size of the tumor and the Pr (p = 0.007); large tumor contains low Pr. The same correlation was found with Er, but it was not statistically significant (p = 0.40). There is also a negative correlation between the number of axillary metastatic lymph nodes and Er and Pr, but this was not statistically significant.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3724175     DOI: 10.1002/jso.2930310317

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

1.  PPARgamma and Wnt/beta-Catenin pathway in human breast cancer: expression pattern, molecular interaction and clinical/prognostic correlations.

Authors:  Ying Jiang; Lin Zou; Chunhui Zhang; Song He; Chun Cheng; Junfei Xu; Weiqi Lu; Yong Zhang; Hua Zhang; Donglin Wang; Aiguo Shen
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-03       Impact factor: 4.553

Review 2.  No association between the progesterone receptor gene polymorphism (+331G/a) and the risk of breast cancer: an updated meta-analysis.

Authors:  Xing-Ling Qi; Jun Yao; Yong Zhang
Journal:  BMC Med Genet       Date:  2017-10-30       Impact factor: 2.103

3.  Foxo3a expression is a prognostic marker in breast cancer.

Authors:  Ying Jiang; Lin Zou; Wei-Qi Lu; Yong Zhang; Ai-Guo Shen
Journal:  PLoS One       Date:  2013-08-13       Impact factor: 3.240

4.  Association of Fascin and matrix metalloproteinase-9 expression with poor prognostic parameters in breast carcinoma of Egyptian women.

Authors:  Nermeen Salah Youssef; Sarah Adel Hakim
Journal:  Diagn Pathol       Date:  2014-07-04       Impact factor: 2.644

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.